MedTrace Logo

Validation of 'Corona-T-test' for Assessment of SARS-COV-2-specific T-cell Response After COVID-19 or Vaccination

NCT05165719 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 220

Last updated 2021-12-21

No results posted yet for this study

Summary

Accuracy validation of the designed and manufactured ELISpot-based in vitro diagnostic 'Corona-T-test' for detection of SARS-CoV-2-specific T cells.

Conditions

Interventions

DIAGNOSTIC_TEST

Corona-T-test

Corona-T-test - a single-color enzymatic ELISpot kit for the detection of interferon-gamma (IFNɣ), produced by the National Research Center for Hematology aiming detection of SARS-CoV-2-specific T cells

Sponsors & Collaborators

  • Federal Research Institute of Pediatric Hematology, Oncology and Immunology

    collaborator OTHER

  • DNKOM LLC

    collaborator OTHER

  • National Research Center for Hematology, Russia

    lead NETWORK

Principal Investigators

  • Grigory A Efimov, MD PhD · National Research Center for Hematology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-07
Primary Completion
2021-09-21
Completion
2021-11-20

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05165719 on ClinicalTrials.gov